ConserV Says Its Vaccine R&D Is 'Aimed At The Next Pandemic’
Enters mRNA Pact with Belgium’s eTheRNA Targeting Highly Mutagenic Viruses
ConserV CEO tells Scrip why the late-stage vaccine developer has entered an mRNA development pact with eTheRNA of Belgium and about the UK biotech’s hopes for finding a universal jab against the entire coronavirus family.
